Imaging Subgroup Formed Under NCI/FDA Oncology Task Force
This article was originally published in The Gray Sheet
Executive Summary
FDA and the National Cancer Institute plan to explore the use of imaging technologies to improve oncology drug development
You may also be interested in...
McClellan’s FDA Legacy? Decisive Role In Product Development Priorities
FDA's "critical path" initiative to help streamline R&D costs and product development schedules is positioning the agency to eventually seek grant-making authority from Congress
Imaging Technologies Tagged For FDA Drug Development Initiative
FDA is commencing an initiative to encourage use of imaging technologies to develop surrogate endpoints for drug submissions
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”